Head and neck cancer
Adlai revives Novartisā abandoned cancer drug, raises $57.5M in IPO to fund phase 3 trial
Anika Sharma
Adlai Nortye has solidified its financial footing, paving the way to determine the fate of its strategic investment in an ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
Anika Sharma
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
